Kusnetzky Lisa L, Khalid Adnan, Khumri Taiyeb M, Moe Tabitha G, Jones Philip G, Main Michael L
Saint Luke's Mid America Heart Institute, Kansas City, Missouri 64111, USA.
J Am Coll Cardiol. 2008 Apr 29;51(17):1704-6. doi: 10.1016/j.jacc.2008.03.006. Epub 2008 Apr 9.
We sought to define acute mortality in hospitalized patients undergoing clinically indicated echocardiography with and without use of an ultrasound contrast agent.
The U.S. Food and Drug Administration recently issued a boxed warning and new contraindications for the perflutren-containing ultrasound contrast agents following post-marketing reports of 4 patient deaths that were temporally related to Definity (Bristol-Myers Squibb Medical Imaging, Billerica, Massachusetts) administration. To appreciate the incremental risk of any medical procedure, the ambient risk of untoward outcome in the population in question must first be defined. There are no published data on short-term major adverse cardiac events in hospitalized patients undergoing echocardiography, either with or without administration of an ultrasound contrast agent.
A retrospective analysis of hospitalized patients undergoing clinically indicated echocardiography between January 2005 and October 2007, within Saint Luke's Health System, Kansas City, Missouri, was performed. Studies were separated into 2 groups, those performed without contrast enhancement (n = 12,475) and those performed with Definity (n = 6,196). Vital status within 24 h of the echocardiographic study was available for all patients using a combination of the Social Security Death Master File and Saint Luke's Health System medical records. Incidence of death within 24 h was compared by chi-square test between Definity and unenhanced procedures.
Of the 18,671 patient events, 72 patients died within 24 h. Of those that underwent unenhanced echocardiography, 46 died within 24 h (0.37%). Of patients receiving Definity during the echocardiogram, 26 died within 24 h (0.42%). There was no statistical difference between these 2 groups (p = 0.60). No patient died within 1 h of the echocardiographic study. In a random sampling from the unenhanced (n = 201) and Definity groups (n = 202), patients who underwent Definity-enhanced echocardiography exhibited higher clinical acuity, and more significant comorbidities.
Approximately 0.4% of hospitalized patients die within 24 h of echocardiography. There is no increased mortality risk associated with Definity-enhanced examinations, despite evidence for higher clinical acuity and more comorbid conditions in patients undergoing contrast studies.
我们试图确定在接受临床指征超声心动图检查时使用和不使用超声造影剂的住院患者的急性死亡率。
美国食品药品监督管理局(FDA)在收到4例与Definity(百时美施贵宝医学影像公司,马萨诸塞州比勒里卡)给药时间相关的患者死亡的上市后报告后,最近发布了关于含全氟丙烷超声造影剂的盒装警告和新的禁忌证。为了了解任何医疗程序的额外风险,必须首先确定相关人群中不良后果的背景风险。关于接受超声心动图检查的住院患者,无论是否使用超声造影剂,短期主要不良心脏事件均无发表的数据。
对2005年1月至2007年10月在密苏里州堪萨斯城圣卢克医疗系统内接受临床指征超声心动图检查的住院患者进行回顾性分析。研究分为两组,未进行造影增强的患者(n = 12,475)和使用Definity的患者(n = 6,196)。使用社会保障死亡主文件和圣卢克医疗系统的医疗记录相结合的方式,可获得所有患者在超声心动图检查后24小时内的生命状态。通过卡方检验比较Definity组和未增强检查组24小时内的死亡率。
在18,671例患者事件中,72例在24小时内死亡。在接受未增强超声心动图检查的患者中,46例在24小时内死亡(0.37%)。在超声心动图检查期间接受Definity的患者中,26例在24小时内死亡(0.42%)。这两组之间无统计学差异(p = 0.60)。在超声心动图检查后1小时内无患者死亡。从未增强组(n = 201)和Definity组(n = 202)中随机抽样,接受Definity增强超声心动图检查的患者表现出更高的临床敏锐度和更严重的合并症。
约0.4%的住院患者在超声心动图检查后24小时内死亡。尽管有证据表明接受造影检查的患者临床敏锐度更高且合并症更多,但Definity增强检查并未增加死亡风险。